Linvoseltamab vs. Standard Treatment for Relapsed/Refractory Multiple Myeloma
This study is comparing an experimental drug called linvoseltamab (also known as REGN5458) to a combination of three standard drugs: elotuzumab, pomalidomide, and dexamethasone. We want to learn which treatment works better for adults with multiple myeloma that has come back or gotten worse after previous treatments (relapsed/refractory multiple myeloma). Linvoseltamab has shown promise in earlier studies, shrinking tumors in some patients who had no other good treatment options. The main goal is to see how long patients live without their cancer getting worse (Progression Free Survival). We are looking for about 410 participants who are 18 or older and meet certain health criteria. The current recruitment status is unclear.
- Study design
- This interventional study plans to enroll about 410 participants. It is comparing two different treatment approaches.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for up to approximately 5 years to monitor how long they live without their cancer getting worse.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma
At a glance
Conditions
Where it's being run
159 sites across 85 statesStudy leadership
- Clinical Trial Management · STUDY_DIRECTOR · Regeneron Pharmaceuticals
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Progression Free Survival (PFS) per International Myeloma Working Group (IMWG) response criteria determined by Independent Review Committee (IRC) in CD38 antibody exposed participantsUp to approximatively 5 years